• ‘We follow stringent standards to ensure safety and quality’ says GM
  • Low-dose aspirin tablet recalled due to stability issues

Ras Al Khaimah (UAE): Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has issued a statement reinforcing its commitment to quality following the recall of one of its products by the UAE Ministry of Health and Prevention (MoHAP).

Jerome Carle, General Manager of Julphar, said: We can confirm that low-dose aspirin medicine, Jusprin 81mg, has been recalled by MoHAP due to an issue over its stability.

 “The global nature of our business requires that the Julphar system has the highest standards and processes to ensure consistent quality across our entire value chain – from the supply of materials through to manufacturing and approval by the leading authorities in the world.

“Our consumers deserve safe, effective and quality products, and across the Julphar system, we work hard to meet the highest standards of safety and quality. We follow stringent procedures designed to ensure the safety and quality of each of our products.

Our scientific teams are working hand in hand with MOHAP and we are following their recommendations to the letter to ensure a quick resolution.”

-Ends-

About Julphar

 

Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents.

Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of insulin in the world.

-Ends-

For more information, visit www.julphar.net 
For media enquiries, please contact:
Chris Goward
Julphar
T: +971 7 246 1461
M: +971 58 263 3997
E: chris.goward@julphar.net 

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.